Genmab has achieved a third pre-clinical milestone that generates a payment worth €1m as part of a collaboration with Lundbeck.
The deal allows Genmab, which received €7.5m upfront payment previously, to develop human antibodies against three central nervous system targets identified by Lundbeck.
Lundbeck, which will entirely fund the antibody development, has access to Genmab's antibody creation and development potential.
Genmab chief executive officer Jan van de Winkel said, "We continue to make solid progress in our collaboration with Lundbeck, having now reached the in vitro proof of concept milestone for the third target in the program."